Skip to main content

$0.003 (0%)

High

$0.00

Low

$0.00

Trades

3

Turnover

$1,511

Volume

672,333
30 June 2023 at 1:49pm
Register to track GTG and receive email alerts.
Subject
GTG Ann: Notification of cessation of securities - GTG

GTG Ann: Updated Investor Presentation and Investor Webinar

GTG Ann: Publication Validates geneType for Melanoma Risk Assessment

GTG Ann: Appendix 4C & Quarterly Activities Report - March 2023

GTG Ann: Change in substantial holding

GTG Ann: Publication Validates geneType Prostate Cancer Risk Test

GTG Ann: GeneType MultiTest Panel Expanded Inclusion of New Diseases

GTG Ann: Response to ASX Query

GTG Ann: Further Study Validates geneType Breast Cancer Risk Test

GTG Ann: Notification of cessation of securities - GTG

GTG Ann: Change in substantial holding

GTG Ann: Half Year Financial Results Investor Webinar Presentation

GTG Ann: Appendix 4D & Half-year Financial Report December 2022

GTG Ann: 2023 Half-year Financial Results Investor Webinar

GTG Ann: Notification of cessation of securities - GTG

GTG Ann: Receipt of R&D Tax Incentive Refund for geneType Multi Test

GTG Ann: Publication Highlights geneType Outperforms Current Models

GTG Ann: Business Update - February 2023

GTG Ann: Change in substantial holding

GTG Ann: Prospectus Supplement

GTG Ann: GTG Announces Closing of US$5M Registered Direct Offering

GTG Ann: Section 708A - Cleansing Notice

GTG Ann: Application for quotation of securities - GTG

GTG Ann: Proposed issue of securities - GTG

GTG Ann: Supplementary Announcement - Comprehensive Risk Test

GTG Ann: Proposed issue of securities - GTG

GTG Ann: Genetic Technologies Announces US$5M Registered Direct Offer

GTG Ann: World First Comprehensive Risk Test-Breast & Ovarian Cancer

GTG Ann: Appendix 3Y Change of Directors Interest Notice

GTG Ann: GTG to form Strategic Alliance with global leader QIAGEN

GTG Ann: Appendix 4C and Quarterly Business Update December 2022

GTG Ann: Colorectal Cancer Model Presented at ASCOGI Cancer Symposium

GTG Ann: Notification of cessation of securities - GTG

GTG Ann: Appendix 3Y - Lindsay Wakefield

GTG Ann: Change in substantial holding

GTG Ann: GeneType Published in PLUS ONE for CVD & Type 2 Diabetes

GTG Ann: Results of AGM

GTG Ann: AGM Presentation and Chairman's Address

GTG Ann: GTG Webinar on Risk Assessment Tests for Serious Disease

GTG Ann: Notification of cessation of securities - GTG

GTG Ann: Genetype for Ovarian Cancer published in European Journal

GTG Ann: Change of Director's Interest Notice

GTG Ann: Genetic Technologies Investor Presentation Webinar

GTG Ann: Notice of Annual General Meeting/Proxy Form

GTG Ann: Genetic Technologies AusBioInvest Presentation

GTG Ann: Quarterly Activities/Appendix 4C Cash Flow Report

GTG Ann: Bloomberg Airs Genetic Technologies Business Update

GTG Ann: Appointment of CFO and Company Secretary

GTG Ann: GeneType Outperforms Traditional Risk Assessments

GTG Ann: Change in substantial holding

Register to track GTG and receive email alerts.

Similar Companies

ADO
BPH
CTE
GSS
MEM
OSL
PAL
PIQ